Longevity & Anti-Aging Technology
Retro Biosciences Platform
by Retro Biosciences, Inc.
Adding ten healthy years to human lifespan through autophagy, plasma, and reprogramming
Category
Longevity & Anti-Aging Technology
Founded
2021
Headquarters
Redwood City, CA, USA
Overview
Retro Biosciences is a longevity-focused biotechnology company with a stated mission of adding ten years to average human healthspan. The company pursues three scientific pillars: cellular reprogramming (partial Yamanaka factor-based rejuvenation), autophagy enhancement (improving the cellular cleanup mechanisms that decline with age), and plasma-inspired interventions (identifying and harnessing youthful circulating factors that decline as humans age). Retro operates its own wet laboratory and partners with leading academic institutions to prosecute these programs concurrently. Retro's approach is distinctive in its focus on translatable therapeutic interventions rather than purely academic discovery. The company has published research on autophagy enhancement as a longevity intervention and is advancing specific small molecule and biologics candidates through preclinical development. Retro's scientific advisors include pioneers in autophagy biology, reprogramming, and systems biology of aging. Founded with $180 million from OpenAI CEO Sam Altman as a single investor, Retro Biosciences operates with an unusually flat, high-trust structure designed for scientific speed. The company's model prioritizes generating proprietary data on aging mechanisms in parallel programs, betting that solving multiple aging hallmarks simultaneously will be required to achieve meaningful healthspan extension in humans.
Key Features
Biological Age Clocks
Multi-omics aging clocks quantify biological age with higher accuracy than chronological measures.
Aging Pathway Modeling
Computational models of aging pathways including mTOR, AMPK, sirtuins, and cellular senescence.
Clinical Trial Design
Novel endpoint designs and biomarker strategies for longevity intervention clinical trials.
Proteomics Age Prediction
Plasma proteomics-based age prediction and organ-specific aging assessment.
Metabolomic Aging Signatures
Identify metabolomic patterns predictive of healthspan and response to longevity interventions.
Pros & Cons
Pros
- +Longitudinal biomarker tracking monitors intervention effectiveness over extended time periods
- +Integration of proteomics, metabolomics, and epigenomics provides comprehensive aging profiles
- +Clinical trial infrastructure supports novel endpoint designs for longevity interventions
- +Multi-omics aging clocks quantify biological age with higher accuracy than chronological measures
- +AI-driven target identification discovers novel longevity pathways from large-scale aging datasets
- +Cellular reprogramming technologies reverse age-related epigenetic changes in human cells
Cons
- −Ethical debates around life extension technologies create public perception and policy challenges
- −Longevity intervention efficacy in humans remains largely unproven despite animal model evidence
- −Long study durations required to demonstrate meaningful lifespan extension create business model challenges
- −Regulatory pathways for aging interventions are unclear as aging is not classified as a disease
- −Biomarker surrogates for aging may not accurately predict actual healthspan extension
Use Cases
Research Workflow Optimization
AI-powered optimization of research workflows to accelerate discovery timelines and improve reproducibility.
Data Analysis & Insights
Machine learning analysis of complex biological datasets to extract actionable insights and identify patterns.
Collaboration & Knowledge Management
Platform-enabled collaboration across distributed research teams with integrated data sharing and knowledge capture.